PLCRC biedt een landelijk platform voor onderzoek

naar dikkedarm- en endeldarmkanker.





DISTANCE-trial: Towards patient-led follow-up after curative treatment of stage II and III colorectal cancer

14 april 2021

Colorectal cancer (CRC) is a common cancer type in the Netherlands. After surgical treatment, approximately 20% of stage II/III CRC patients develop a recurrent tumour or metastases. Patients are currently followed for five years after curative resection. However, intensified follow-up after curative resection has shown no effect on survival. Therefore, patient organisations and policy makers call for a more patient-centred, tailored follow-up.

Patient-led, home-based follow-up shows great potential as an alternative for the regular-in hospital follow-up. Implementation of patient-led, home-based follow-up at the Radboud University Medical Center in Nijmegen, the Netherlands led to a 70% decrease in patients having contact with the hospital, and a decrease of more than 60% in cost of CRC follow-up.

Read more

PLCRC-ORCA: Liquid biOpsies in Ras wildtype non-liver limited metastasized colorectal CAncer patients: an exploratory study.

1 september 2019

One of the treatment options for patients with metastatic colorectal cancer (mCRC) is an EGFR blocker. It is known that patients with a mutation in one of the RAS genes do not benefit from the treatment with an EGFR blocker. About 50% of patients with mCRC have a mutation in RAS. In addition to primary resistance, RAS mutations encourage induced resistance to anti-EGFR therapy. Apart from repeated biopsies, no other methods are currently available to track molecular changes during anti-EGFR treatment.

Read more

MEDOCC: molecular Early Detection of Colon Cancer

10 mei 2019

The incidence of large bowel cancer is increasing. A staging system is used to indicate severity of disease, in which stage 1 until 3 comprise a group of patients without metastases to other organs. These stages of large bowel cancer can be curatively treated with surgery by resecting the tumor and involved lymph nodes.

Read more

PLCRC-QUALITAS: QUAlity of LIfe in meTAStatic colorectal cancer patients treated with trifluridine-tipiracil in late line in the PLCRC cohort

23 juni 2018


One of the most recent treatment options for metastatic colorectal cancer is trifluridine tipiracil (= TAS-102 = Lonsurf®). This is a combination tablet of two medicines that together prevent the growth of tumor cells. Previous research has shown that trifluridine tipiracil is effective in the treatment of colorectal cancer: treated patients live on average 1.8 months longer than patients who do not receive trifluridine tipiracil. Since February 2017, trifluridine tipiracil is available in the Netherlands. Only patients who are unresponsive to or intolerant to standard therapies are eligible for treatment with trifluridine tipiracil.

Lees meer

Research on the outcomes of patients with rectal cancer

5 februari 2016

Every year, over 4,300 people in the Netherlands are diagnosed with rectal cancer, and more than 1,000 patients die from this disease. Treatment of rectal cancer consists of surgery, usually preceded by radiotherapy with or without chemotherapy. This treatment is associated with a substantial risk of short- and longterm side effects. Research into more effective treatment with fewer side effects is therefore of great importance.

Read more

Improving clinical management of colon cancer through CONNECTION, a nation-wide Colon Cancer Registry and Stratification effort.

17 november 2015

Colorectal cancer is still a devastating disease with over 600.000 deaths per year worldwide. This is in part due to poor survival of patients with late stage disease where curative treatment options are limited, but even at stage II around 20% of the patients will develop a recurrence despite effective surgical resection of the primary tumor. Identification of these stage II patients at risk and optimization of the therapy provided is therefore an important goal to improve outcome in colon cancer.

Read more

‘’Specialized nutrition to improve Clinical Outcomes in colorectal cancer PatiEnts (SCOPE)’’ project

9 november 2015

Approximately 15,000 patients per year are diagnosed with colorectal cancer (CRC) in the Netherlands. Treatment can consist of surgery, often complemented with radiation or systemic therapy. Patients with colorectal cancer often perceive weight loss, reduced muscle mass, fatigue and loss of appetite as a result of their disease and treatments. It is currently assumed that maintaining muscle mass and a well-balanced nutritional status after diagnosis contributes to the success of treatment.

Read more